The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy. To treat the disease successfully, new therapeutic strategies are urgently needed. One of these strategies can be the use of neurokinin-1 receptor (NK-1R) antagonists (e.g., aprepitant), because the substance P (SP)/NK-1R syst...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Miguel Muñoz, Rafael Coveñas
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI AG 2020-06-01
Colección:Journal of Clinical Medicine
Materias:
substance P
NK-1R
AML
aprepitant
anti-leukemic
apoptosis
Acceso en línea:https://www.mdpi.com/2077-0383/9/6/1659
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares